China Launches Nationwide Unannounced Inspections of Medical Insurance Funds
An inaugural meeting for the first batch of unannounced medical insurance fund inspections was conducted...
Policy / Regulatory
NMPA Seeks Public Comment on Draft Proposal for Drug Re-Registration Procedures
The National Medical Products Administration (NMPA) of China has released a draft proposal for the...
NMPA Updates In Vitro Diagnostic Reagents Classification List for Enhanced Regulatory Oversigh
The National Medical Products Administration (NMPA) has coordinated the revision and release of the In...
China’s NMPA Revamps Medical Device Classification Rules to Improve Regulatory Efficiency
The National Medical Products Administration (NMPA) has revised the “Notice on Standardizing the Classification of...
BIO Survey Highlights Extensive Dependence on Chinese CDMOs in Life Sciences
The Biotechnology Innovation Organization (BIO), a US industry trade group, has completed a survey among...
BioSecure Act Advances in US, Aiming to Curb Ties with Chinese Bioscience Firms
US legislators are working expeditiously to finalize the BioSecure Act, legislation that, if enacted, would...
China Unveils Sweeping 2024 Legislative Plan with Healthcare and Pharma at Forefront
The State Council of China has released its annual legislative work plan for 2024, outlining...
Hong Kong SAR and NMPA Renew Agreements to Boost Drug and Medical Device Regulation
Professor Chung-mau LO, BBS, JP, Secretary for Health of the Hong Kong Special Administrative Region...
Xi and Macron Discuss Enhanced Market Access for Foreign Investors, Focus on Life Sciences
This week, talks between China’s President Xi Jinping and France’s President Emmanuel Macron in France...
China Upgrades Midazolam to Category I Psychotropic Drug List in Regulatory Rescheduling
In a joint notification, the National Medical Products Administration (NMPA), Ministry of Public Security, and...
Lei Haichao Takes Over as Party Secretary of China’s National Health Commission
The National Health Commission (NHC) of China has undergone a leadership change, with Lei Haichao...
BIO Surveys Members on China-CDMO Dependence Amid BioSecurity Bill Deliberations
The Biotechnology Innovation Organization (BIO), a prominent US industry trade group, is conducting a survey...
CDE Seeks Public Comment on Latest Generic Chemical Reference Preparations
The Center for Drug Evaluation (CDE), China’s regulatory body, is currently seeking public feedback on...
US Legislature Reviews BioSecurity Bill to Sever Biotech Industry Ties with Chinese Companies
On May 15, 2024, the US House Oversight Committee is set to review a “BioSecurity”...
China’s National Procurement Office Announces Continuous VBP for Joint Prosthetics
The National High-Value Medical Consumables Joint Procurement Office in China has initiated a new round...
GBA Center of NMPA Launches Filing Guidance for Pharmaceutical Enterprises
The Guangdong-Hong Kong-Macau Greater Bay Area (GBA) Center for Drug Evaluation and Inspection, under the...
China’s Q1 2024 Pharma Trade Registers 6.3% Growth Amid Global Recovery
The China Chamber of Commerce for Import and Export of Medicines and Health Products (CCCMHPIE)...
China’s National Drug Alliance Procurement Office Announces Insulin VBP Re-Tender Results
The National Drug Alliance Procurement Office in China has published the winning results of the...
China Launches Unannounced Inspections on Medical Insurance Funds, Targets Fraud and Mismanagement
The National Healthcare Security Administration (NHSA), National Health Commission (NHC), along with two other bureaus,...
Former Sinopharm Executive Yang Xiaoming Removed from National People’s Congress Over Alleged Serious Violations
Yang Xiaoming, previously the chief engineer and chief scientist of China National Pharmaceutical Group Corporation...